WO2015022830A1 - Composition for promoting estrogen secretion, aromatic composition, and aroma tool - Google Patents

Abstract

[Problem] To provide: a composition that is for promoting estrogen secretion and that can promote the secretion of estrogen; an estrogen secretion aromatic composition; and an estrogen aroma tool. [Solution] By means of a method mediated by the olfactory nerve, the composition for promoting estrogen secretion promotes the secretion of estrogen and contains, as the active ingredient, synthetic 1,8-cineole or 1,8-cineole that has been isolated and purified from a natural product.

Description

Composition for enhancing estrogen secretion, fragrance composition thereof, and fragrance device therefor

The present invention relates to an estrogen secretion enhancing composition, an estrogen secretion aroma composition, and an estrogen secretion aroma device containing 1,8-cineole as an active ingredient.

Indefinite peculiar to women, generally occurring in the late corpus luteum (from 7-10 days before menstruation to the start of menstruation), immediately after childbirth (3 weeks after childbirth, 2-5 weeks), and menopause (usually 45-55 years) Complaints (depressed mood, malaise, decreased motivation, sleep disorders) are caused by decreased estrogen secretion.

At the end of menstruation, stimulation of the hypothalamus gradually increases the amount of estrogen secretion and ovulation occurs. The follicles that have finished ovulation become the corpus luteum and secrete progesterone, but at this time estrogen is also secreted. The level gradually increases, but if you don't get pregnant, it drops sharply and menstruation begins. Therefore, the late corpus luteum is a time when a rapid decrease in estrogen secretion occurs. Premenstrual tension occurs at this time. In this disease, female-specific indefinite complaints occur in the late luteal phase and gradually disappear with the onset of menstruation, but may continue during the menstrual period. 20-50% of women of reproductive age have at least one symptom of premenstrual tension.

When fertilized after ovulation, estrogen levels increase rapidly and in large quantities. Estrogen secretion during pregnancy is tens of times that of women who are not pregnant. Estrogen secretion levels, which have been elevated for almost 9 months, decrease rapidly within hours after delivery and fall to the point where they cannot be measured on day 7. Maternity blue occurs in about 80% of women at this time. Maternity blue, like premenstrual tension, presents unspecified complaints specific to women. Symptoms usually begin 3-5 days after delivery and disappear within 2 weeks. In addition, postpartum depression may occur due to decreased postpartum hormone secretion.

分泌 Estrogen secretion levels change throughout life. It begins to rise in puberty and reaches its peak in the 20s. Later, ovarian function gradually declined, estrogen decreased, and menopause. Menopause usually occurs between the ages of 45 and 55 and may be early or late. Menopause is seen in 60-70% of women at this time. Symptoms of menopause are mainly women's unspecified complaints similar to premenstrual tension or maternity blue.

From the above, it can be seen that indefinite complaints (including illness) in women appear in the late corpus luteum (including during menstruation), postpartum, and menopause, which is characterized by decreased estrogen secretion.
By the way, as a composition for controlling estrogen secretion, Patent Document 1 discloses amplet seed oil as a fragrance composition as a secretion promoter for 17β-estradiol, which is a main component of estrogen (a group of female hormones). The use of an amblet lid is disclosed. Patent Document 2 discloses the use of an extract of fungal Cordyceps as a treatment for female hormone deficiency. Patent Document 3 is based on the present inventors, and discloses the effect of aroma component of β-caryophyllene on women.

Furthermore, Non-Patent Documents 1 to 3 show that the presentation of odor changes the secretion frequency of luteinizing hormone (LH) controlled by the hypothalamus, and conventional aromatherapy and the like are oral, intravenous, and transdermal. In contrast to the complex action via the root, the possibility of changing hypothalamic function only through the action via the olfactory nerve was shown. In general, estrogen secretion is caused by the secretion of LH, and LH secretion is caused by the activity of the hypothalamus. Therefore, the effect of increasing the activity of the hypothalamus is considered to cause the increase of estrogen secretion. . Neither mentions about estrogen secretion, which is 1,8-cineole and the female hormone.

Estrogens have been shown to have the following anti-aging effects (or disease risk reduction effects associated with reduced estrogen in menopause and menopausal women).
・ Promoting the production of collagen (beautifying skin effect, preventing firmness / shininess)
・ Promoting absorption of calcium into bone (reducing risk of osteoporosis)
・ Promoting hair renewal (promoting hair growth)
・ Increased basic metabolism (prevention of apple-type obesity)
・ Cognitive enhancement (reducing dementia risk)
・ Promoting vasodilation (reducing the risk of arteriosclerosis)
・ Immune function enhancement (reducing risk of autoimmune diseases such as collagen disease and rheumatism)
・ Promoting the development of the mammary gland (beauty effect by maintaining the elasticity and elasticity of the breast)
・ Increased good cholesterol (HDL) (reduced risk of arteriosclerosis)

Recently, as an alternative medicine, health improvement methods by aroma (scented substances) such as aromatherapy are spreading, but the benefits are based on experience and are not supported by basic medical research. In addition, the route of action is not limited to the route through the olfactory nerve, but also includes the oral, intravenous, and transdermal routes. However, when olfactory information is input directly to the limbic system, which is the center of emotion, and to the hypothalamus, which is the center of instinct (feeding, sleep) hormone, without passing through the cerebral neocortex, There is a possibility that it can be developed as a new central nervous system drug without transvenous or transdermal route.

JP 2005-29776 A JP 2004-300104 A Japanese Patent No. 5116942

An object of the present invention is to provide a composition for enhancing estrogen secretion and the method for enhancing secretion.

As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that the odor of 1,8-cineole particularly enhances estrogen secretion in late-luteal females. The present invention has been completed based on the above findings, and is an estrogen secretion enhancing composition containing 1,8-cineole as an active ingredient, its fragrance composition, and its fragrance tool.

That is, the first aspect of the present invention is the invention according to claim 1, wherein estrogen secretion containing 1,8-cineole synthesized or purified from natural product as an active ingredient is synthesized. It is a composition for enhancing estrogen secretion, characterized by enhancing.
The invention of claim 2 is the composition for enhancing estrogen secretion according to claim 1, wherein the estrogen is 17β-estradiol.
The invention of claim 3 is the composition for enhancing estrogen secretion according to claim 1 or 2, wherein the administration means of the composition is administered so as to be transmitted to the brain via the olfactory nerve by a fragrance, essential oil, or cosmetics. It is characterized by that.
The invention of claim 4 is characterized in that, in the composition for enhancing estrogen secretion according to claim 3, the administration means of the composition is administered so as to be transmitted to the brain via the olfactory nerve by food and drink.
The invention according to claim 5, which is the second aspect of the present invention, comprises synthesized 1,8-cineol or 1,8-cineole isolated and purified from a natural product as an active ingredient to inhibit estrogen secretion. An estrogen-secreting fragrance composition characterized in that it is enhanced.
The invention of claim 6 is the estrogen secretion fragrance composition of claim 5, wherein the estrogen is 17β-estradiol.
The invention according to claim 7, which is the third aspect of the present invention, comprises 1,8-cineole synthesized or 1,8-cineole isolated and purified from a natural product as an active ingredient to inhibit estrogen secretion. It is an estrogen fragrance tool characterized by improving it.
The invention of claim 8 is the estrogen-secreting fragrance device according to claim 7, wherein the estrogen is 17β-estradiol.

Estrogen secretion enhancing composition, estrogen secretion fragrance composition, and estrogen fragrance composition containing 1,8-cineole isolated and purified from the synthesized 1,8-cineol or natural product of the present invention as an active ingredient Can be used to enhance estrogen secretion, and in particular, estrogen secretion can be further enhanced in the late corpus luteum. For this reason, estrogen is effective in alleviating female-specific indefinite complaints (including illness) such as premenstrual tension, menstrual symptoms, maternity blue, postpartum depression, and menopause, which are caused by decreased estrogen secretion in women. Anti-aging effect due to increased secretion can be expected.
As a secondary effect, especially in the late luteal phase, concentration, libido, positive / negative emotions, mood, and anxiety symptoms can be improved, thereby improving the indefinite complaint symptoms and anti-aging effects of women. it can.
In addition, since the composition of the present invention can be administered by a method via the olfactory nerve, it can exert its effect in a short time, and since it does not involve blood, it has the advantage of having no side effects on organs such as the liver and kidney. There is also.

Smell a solution containing 1.5% 1,8-cineole in all subjects (n = 11), follicular phase subjects (n = 6), and late luteum phase subjects (n = 5) A graph of the bar graph of the value obtained by subtracting the amount of change when smelling propylene glycol (PG) control solution from the amount of change for estrogen (after sniffing-before sniffing), From the amount of change in estrogen when a solution containing 0.30%, 1.50%, 3.75%, and 7.50% of 1,8-cineole was added, propylene glycol (PG : Control) Bar graph of the value obtained by subtracting the amount of change when smelling sputum solution, The graph of the experimental result which verified the concentration power by the ANT (attentionＡnetwork task) test by sniffing the solution which dissolved 1,8-cineole of the example in the solvent and only the solvent for five subjects in the late corpus luteum Figure of the Figure of the graph of the experimental result which verified the subject's "sexual desire" by sniffing the solution which dissolved 1,8-cineole of the example in the solvent, and only the solvent similarly for the 6 subjects in the late corpus luteum, Figure of graph of the experimental result that we verified increase and decrease of feeling by administration of 1,8-cineole for 6 subjects in the late corpus luteum in the PANAS (The sPositive and Negative Affect Schedule) test, In the graph of the results of the experiment on POMS's “liveliness”, “anxiety”, “depression”, and “feeling fatigue” by sniffing a solution of 1,8-cineole in a solvent and only the solvent for six subjects in the late corpus luteum Figure, It is a figure of the graph of the experimental result which verified the state anxiety by STAI (State (trademark) andTrait (trademark) Anxiety (s) Inventry) test by administration of 1,8- cineole to six subjects of the luteum phase.

In the following, the present invention will be described in detail, and the present invention shows that the odor of 1,8-cineole is particularly estrogen in a woman in the late luteal phase (in the late luteal phase, estrogen decreases and premenstrual tension develops). We found an action to enhance secretion. The present invention has been completed based on the above findings.
This 1,8-cineole is a naturally occurring organic compound called eucalyptol (also synthesizable), which is a kind of monoterpenoid with a cyclic ether structure, and is 1,8-cineole. It is also called limonene oxide and cajeptol, and has a fragrance and taste that makes it suitable for food additives, fragrances, and cosmetics, and has the following structural formula.

The inventors have found that the odor of 1,8-cineole has the effect of promoting estrogen secretion in late luteinous women, but has come up with the idea that it can be used for the following novel uses.
(1) 1,8-cineole can be presumed to be effective in improving discomfort caused by decreased estrogen secretion in women in the late corpus luteum (including menstrual periods) and in women after childbirth . Discomfort caused by decreased estrogen secretion is seen not only in women in the late corpus luteum (including menstrual periods), but also in women after childbirth and women in menopause. It can be assumed that 1,8-cineole is effective. Moreover, it can be estimated that the above-mentioned anti-aging effect is obtained.
(2) The use of plant essential oil (essential oil) to improve symptoms and maintain good health is generally called aromatherapy (aroma therapy, aroma therapy). Instead of this plant essential oil (mixture), 1,8- It is also possible to treat disease using cineol (a single substance contained in essential oils).
Therefore, 1,8-cineole is considered to be usable as “a symptom-improving composition by aroma of enhanced estrogen secretion”.
(3) Similar to (2) above, 1,8-cineole can improve symptoms and maintain health even in the form of instruments and tools. Therefore, it is considered that 1,8-cineole can also be used as a “tool for improving symptoms due to aroma”.

Hereinafter, each of the above uses will be described.
(4) Composition for enhancing estrogen secretion (hereinafter sometimes referred to as “the composition for enhancing the present invention”)
The composition for enhancing estrogen secretion according to the present invention contains 1,8-cineole as an active ingredient.
The 1,8-cineole to be used may be extracted from natural products (for example, tea tree, peppermint, eucalyptus, rosemary, etc.) or may be artificially synthesized. In addition, 1,8-cineole is already sold as a reagent and may be used.

The composition for enhancing estrogen secretion of the present invention is prepared in various compositions depending on the use mode, and is usually prepared in the same composition as the estrogen secreting fragrance composition described later.
The estrogen-secreting fragrance composition of the present invention is prepared in various compositions depending on the use mode, but usually the 1,8-cineole concentration is 0.3 to 3.75%, preferably 1.5. % By mixing with a suitable solvent such as dipropylene glycol, propylene glycol, butylene glycol, mineral oil, triethyl citrate, ethanol, benzyl benzoate.
Generally, the aroma is inhaled as an aromatic bath using an aroma pot or a diffuser. Further, if necessary, other components can be added and used as cosmetics (skin care products, perfumes, etc.), bathing agents, fragrances, sprays, massage oils, shampoos, laundry detergents and the like.

(5) Estrogen secretion fragrance tool The estrogen secretion fragrance tool of the present invention has a portion containing synthesized 1,8-cineole or 1,8-cineole isolated and purified from natural products.
The 1,8-cineole to be used is synthesized or isolated from a natural product and purified in the same manner as the fragrance composition.
In addition, the food is usually smelled before it is put into the mouth or during mastication. Therefore, 1,8-cineole can exert its effect even in the form of food or beverage, and 1,8-cineole can also be used as a food or drink for improving indefinite complaint symptoms of women.
The types of food and drink are not limited, and examples include flavor tea, flavor coffee, flavor beer, rice cake, gum, breath care, seasoning and the like. For example, the food of the present invention is produced by adding a process of adding 1,8-cineole to the normal food production process, and the content of 1,8-cineole in the food depends on the type of food. Normally, the appropriate amount is about 0.3-3.75%.
The fragrance device may be any device or tool used for fragrance, sanitary products, paper, textile products (underwear, stocking, etc.), patch medicine, soap, candle, pillow, futon, Etc. can be illustrated.
The fragrance tool of the present invention can be produced in the same manner as a general fragrance tool, except that 1,8-cineole is used instead of plant essential oil.

(6) Use of the composition for enhancing estrogen secretion The use target and the administration method of the composition for enhancing estrogen secretion of the present invention are characterized in that 1,8-cineole is administered to a person who shows a decrease in estrogen. It is.
The administration method of 1,8-cineole is not particularly limited, and it may be administered orally, intravenously, or transdermally in the same manner as ordinary pharmaceuticals, etc., but preferably stimulated by 1,8-cineole. It is administered by a means that is transmitted to the brain via the olfactory nerve. As an example of such administration means, a means for allowing a person who shows a decrease in estrogen secretion to air containing 1,8-cineole can be exemplified. The amount of 1,8-cineole in the air at this time cannot be measured strictly, but the content of 1,8-cineole used in the solution that emits a fragrance is, for example, when propylene glycol is used as a solvent. Is preferably in the range of 0.3 to 3.75%, more preferably about 1.5%.

Hereinafter, the present invention will be described in more detail with reference to examples.
[Example 1]
We examined hormonal changes that occurred when 1,8-cineole was sniffed in non-smoking women in their twenties who were healthy and mentally healthy who returned to the normal menstrual cycle (26th to 34th).

1.Experimental method 1-1. Briefing session Explaining the contents of the experiment in advance and obtaining consent from the subject, then on the day of the experiment, food or stimulants (garlic, onion, spices, herbs, etc.) with a strong smell were served in the morning. I tried not to eat anything from 30 minutes before the start of the experiment. In addition, the basal body temperature was described, and the ovulation day (LH surge) was confirmed using an ovulation test.

1-2. On the day of the experiment Subjects were divided into two groups according to the menstrual cycle: follicular phase (5-10 days after menstruation started) and late corpus luteum (9-12 days after LH surge). Each group of subjects was sniffed with a solvent containing 1.5% of 1,8-cineole (propylene glycol) or only the solvent, and saliva was collected before and 20 minutes after the start of the experiment, and secreted estrogen ( Among female hormones, 17β estradiol (E2), which has the strongest action, was measured by enzyme immunoassay.

The enzyme immunoassay used above was a salivary component quantification kit (measurement kit) manufactured by SALIMETRICS, whose model number was 1-3702 Estradiol, EIA Kit, High Sensitivity, Salivary, and the measurement method was (A ) “A saliva sample containing an unknown concentration of 17β-estradiol” is reacted with an antibody that binds to it (coated on a hole in a plastic plate called a 96-well plate). The known concentration of 17β estradiol ”was also reacted at the same time, and a competitive reaction was carried out between (A) and (B) (antibodies were exchanged between (A) and (B)).
After the reaction for a certain time, the solution other than the one bound to the plate-like antibody is discarded, and a substrate for inducing an enzyme reaction (color development) is added. By doing so, the color development becomes a hue reflecting the binding amount of (B). This hue is quantified from the measurement with an absorptiometer. If (A) is small, (B) takes more antibody, so the intensity of color development becomes strong, while if (B) is large, the relative color In particular, the amount of antibody taken by (B) decreases and the intensity of color development decreases. Using this principle, separately, a plurality of concentrations of “known concentrations of 17β estradiol (standard sample)” are measured, and a calibration curve is calculated. The concentration of the “saliva sample containing estradiol” was calculated.

“Horseradish peroxidase” which is an enzyme used in the enzyme immunoassay has the following physical properties.
Peroxidase (Hydrogen peroxidase, Horseradish peroxidase, HRP)
Reaction Chromogenic substrate + H ₂ O ₂ Oxidized dye + 2H ₂ O
Origin Horseradish
Molecular weight, 40,000, optimum pH: pH 6.5
Substrate specificity There is no specificity for chromogenic substrates (hydrogen donors).
As peroxides, only H ₂ O ₂ , CH ₃ OOH, C ₂ H ₆ OOH Inhibitors and activators Inhibitors: CN-, S--, F-, N ^3- (fluorine used as anticoagulant Ion, containing NaN3 used as a preservative)
Stability Several years in dry and refrigerated state, one year refrigerated in aqueous solution

In the experiment, air was sent to a glass bottle containing a solvent (propylene glycol) containing 1,8-cineole of this example at a flow rate of 2 L / min. The funnel was separated from the subject's nose by 10 cm. This was continued for 20 minutes. During the experiment, subjects took a breath as usual while sitting in a chair and relaxed, and saliva was collected before and 20 minutes after the start of the experiment. At this time, if any abnormality was observed, the experiment was stopped on the spot and appropriate measures were taken.

1. Experimental result
[Example 1]
Example 1: A comparative experiment was conducted using 1.5% of 1,8-cineole dissolved in propylene glycol and Comparative Example 1: only propylene glycol (PG) as a control.
The test subjects are 11 persons in total of 6 persons in the follicular phase and 5 persons in the late luteal phase (Late Luteal Phase), and the experimental results of Comparative Example 1 and Example 1 are shown.
The comparison results of Example 1 and Comparative Example 1 before and after the experiment showed that the concentration of 17β estradiol (E2) secreted in Example 1 was significantly increased from 3.1 pg / ml to 3.4 pg / ml ( In contrast to the paired t-test, P <0.05), Comparative Example 1 showed no difference in concentration from 3.0 pg / ml to 3.0 pg / ml.
When these changes (after sniffing-before sniffing) were compared (PG vs 1,8-Cineole), the concentration of 17β estradiol (E2) was significantly increased compared to propylene glycol (PG) in the control (corresponding to A t test, P <0.05).

In the experiments of Comparative Example 1 and Example 1 in which six subjects (n = 6) were subjects in the follicular stage, 17β estradiol secreted in Example 1 was changed from 3.1 pg / ml to 3.5 pg / ml. Concentration increased significantly (corresponding t-test, P <0.05), Comparative Example 1 showed an increasing trend from 2.5 pg / ml to 2.7 pg / ml (corresponding t-test) , P <0.10). When these changes (after sniffing-before sniffing) were compared (PG vs 1,8-Cineole), there was no difference in concentration between 1,8-cineole (Cineole) and propylene glycol (PG).

In the experiment of Comparative Example 1 and Example 1 with 5 subjects in the luteal phase (n = 5), 17β estradiol secreted in Example 1 was changed from 3.1 pg / ml to 3.3 pg / ml. Concentration increased, and Comparative Example 1 decreased in concentration from 3.5 pg / ml to 3.1 pg / ml (paired t-test, P <0.10). When these changes (after sniffing-before sniffing) were compared (PG vs 1,8-Cineole), the concentration of 17β estradiol (E2) increased significantly compared to propylene glycol (PG) in the control (corresponding to A t test, P <0.05).

The difference between these changes (1,8-cineole change-propylene glycol (PG) change) is described with reference to FIG. 1. When follicular phase (n = 6) and late corpus luteum (n = Comparing the difference value of each change amount in 5), it can be seen that the concentration (E2) increased significantly in the later luteal phase compared to the follicular phase (unpaired t-test, P <0.05).

Next, it was verified how much 1,8-cineole (Cineole) should be dissolved in propylene glycol (PG).
Therefore, as described above, 1.50% of 1,8-cineole dissolved in propylene glycol (PG) as a solvent as in Example 1 and 0.30% less than that were dissolved, The experiments were carried out on three more subjects in the late luteal phase, with 3.75% and 7.50% more dissolved.
The results of the amount of change are shown in FIG. 2, and it can be seen that the increase in 17β estradiol was significantly increased in the proportion of 1,8-cineole (1.50%), at least 0.30. It can be seen that from 17% to 3.75% an increase in 17β estradiol is observed, whereas 7.50% is counterproductive. That is, it can be seen that a solution of 0.30% to 3.75% shows an effect of enhancing estrogen secretion, and a solution of around 1.50% is preferable.

Next, the subject's “concentration” by administration of 1,8-cineole was verified.
In order to verify this “concentration”, the change in concentration before and after sniffing 1.8-cineole was compared with the case of PG (control) using an ANT (attention network task) test, which is a cognitive task by PC operation. went.
The above-mentioned ANT is a verification means developed to efficiently evaluate human attention functions (execution function, awakening function, attention localization function) in a short time. When an experimental trial is started, the center point is displayed for 1000 ms in the center of the background. Next, “*” is displayed as a cue stimulus. 500 ms after the cue stimulus is presented, images of five arrows are presented above or below the gazing point. The subject's task is to answer the direction of the center arrow among the five arrows as quickly and accurately as possible using the numeric keypad buttons (RT: reaction time).
The central arrow is called a target stimulus, and the other four arrows are called distractor stimuli. In the experiment, a total of four cue stimulus conditions are presented. First, in the No Cue condition, the cue stimulus is not displayed. Next, under the Central Cue condition, a cue stimulus is presented at the position of the gazing point, that is, at the center of the screen. In the Congruent Cue condition, the cue stimulus is presented at the position where the target stimulus is presented. That is, when the arrow is presented above the gazing point, the cue stimulus is also presented above the gazing point. Lastly, in the Incongruent Cue condition, a cue stimulus is presented at a position symmetrical to the target stimulus with respect to a horizontal line crossing the center of the screen. That is, when the target stimulus is presented above the gazing point, the cue stimulus is presented at a position opposite to the target stimulus across the gazing point.

Based on the above-mentioned experiment, five subjects in the late corpus luteum were examined for selective attention score (Conflicting Score), and the results are shown in FIG.
[Conflicting Score]
RT of Incongruent Flanker condition-RT of Congruent Flanker condition was examined. This is considered as an index of selective attention ability, and it is considered that Conflicting Score decreases as the selective attention ability increases.

The results of these experiments are shown in the graph of FIG. 3, and selective caution was observed because Conflicting Score decreased compared to the control (PG) before and after sniffing 1,8-cineole of the example of the present invention. It is thought that ability increased, and it can apply to improvement of concentration from these results.

Next, the “sexual desire” of the subject by administration of 1,8-cineole was verified. This verification uses the Unconscious Dot Probe task, which is a cognitive task by PC operation, and the change in the index that seems to reflect the libido before and after smelling 1,8-cineole (1.5%) and the case of PG (control) The comparison was performed on six subjects in the late luteal phase.
The Unconscious Dot Probe task is a verification tool developed to assess human attention bias. In the experiment in this example, a male nude image was used as the visual stimulus used for the task, and how much attention (bias) to the image is considered as an index reflecting sexual desire was measured. However, the stimulus image presentation time was 17 ms (below the perceptible threshold), and the measurement was performed using the Dot Probe task under the threshold (Uncoscious).

In the problem of the verification means, when an experimental trial is started, a male nude image is presented on either the left or right side of the screen. Next, an inclined striped pattern is presented at either the position where the nude image is presented (Congruent condition) or the opposite position where the nude image is not presented (Incongruent condition) (it disappears immediately after being presented).
The subject's task is to respond as quickly as possible (RT (reaction time)) with the numeric keypad as to which direction the tilted stripe pattern is tilted. The correct answer rate is expected to decrease because the inclination of the striped pattern will be overlooked, so we compared the strength of the bias to male nude images using this correct answer rate as an index.
The results of these experiments are shown in the graph of FIG. 4, and before and after sniffing the 1,8-cineole of the example of the present invention, the bias to the male nude image was increased compared to the control (PG).

Next, regarding the influence of 1,8-cineole administration on the increase or decrease in emotion, a PANAS (The Positive and Negative Affect Schedule) test was performed on six subjects in the late corpus luteum. PANAS is a test that answers emotional question items from two scales of “positive emotion” and “negative emotion”.
The results of these experiments are the graphs of FIG. 5, and before and after sniffing 1,8-cineole of the example of the present invention, positive emotions increased and negative emotions decreased compared to control (PG).

Next, the effect of 1,8-cineole administration on the increase or decrease in mood was verified by a POMS (Profile of Mood States) test on six subjects in the late corpus luteum. POMS is a test that answers the question items of mood from six scales of “liveness”, “anxiety”, “depression”, “anger”, “fatigue”, and “confused”.
The results of these experiments are shown in the graph of FIG. 6. Before and after sniffing 1,8-cineole (1.5%), the example of 1,8-cineole of the present invention was more positive than the control (PG). As a result, vitality increased slightly and anxiety, depression, and fatigue decreased slightly. From these results, it can be used to improve the mood of “liveness”, “anxiety”, “depression”, and “feeling of fatigue”.

Next, the tendency of anxiety due to the administration of 1,8-cineole was verified by STAI (State and Trait Anxiety Inventry) test for 6 subjects in the late corpus luteum.
STAI is a test that answers questions about anxiety status and characteristics from two scales of “state anxiety” and “characteristic anxiety”.
Explaining these experimental results with the graph of FIG. 14, before and after sniffing 1,8-cineole, state anxiety decreased compared to control (PG).
As can be seen from the results of each of these tests, anxiety can be reduced.

As described above, according to the embodiments of the present invention, a composition for enhancing estrogen secretion containing 1,8-cineole synthesized or isolated from natural products and purified as an active ingredient. The estrogen secretion fragrance composition and the estrogen fragrance device can be used on women to enhance estrogen secretion. For this reason, the effects of alleviating women-specific indefinite complaints (including illness) such as premenstrual tension, menstrual symptoms, maternity blue, postpartum depression, and menopause, which are associated with decreased estrogen secretion, increased estrogen secretion, especially The anti-aging effect can be expected due to the enhanced estrogen secretion in the late corpus luteum.

As a side effect, increased estrogen secretion can improve symptoms of concentration, libido, positive / negative emotions, mood, and anxiety, thereby (or at the same time) women's indefinite complaint symptoms. It can be expected to have the effect of improving the anti-aging.
In addition, since the composition of the present invention can be administered by a method via the olfactory nerve, it can exert its effect in a short time, and since it does not involve blood, it has the advantage of having no side effects on organs such as the liver and kidney. There is also.

Claims (8)

1. A composition for enhancing estrogen secretion, which enhances the secretion of estrogen, which contains 1,8-cineole synthesized or isolated from natural products and purified as an active ingredient.
2. The composition for enhancing estrogen secretion according to claim 1, wherein the estrogen is 17β-estradiol.
3. 3. The composition for enhancing estrogen secretion according to claim 1, wherein the administration means of the composition is administered so as to be transmitted to the brain via an olfactory nerve by a fragrance, an essential oil, or a cosmetic.
4. 3. The composition for enhancing estrogen secretion according to claim 1 or 2, wherein the administration means of the composition is administered so as to be transmitted to the brain via an olfactory nerve by food and drink.
5. An estrogen-secreting fragrance composition characterized by containing 1,8-cineole synthesized or isolated from natural products and purified as an active ingredient and enhancing estrogen secretion.
6. The estrogen-secreting fragrance composition according to claim 5, wherein the estrogen is 17β-estradiol.
7. An estrogen fragrance device characterized by containing 1,8-cineole synthesized or isolated from natural products and purified as an active ingredient and enhancing estrogen secretion.
8. The estrogen-secreting fragrance device according to claim 7, wherein the estrogen is 17β-estradiol.

Images